Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 56 Ovarian Neoplasms 36 Carcinoma, Hepatocellular 35 Neoplasms 25 Fallopian Tube Neoplasms 20 Carcinoma, Non-Small-Cell Lung 19 Endometrial Neoplasms 14 Glioblastoma 11 Breast Neoplasms 11 Brain Neoplasms 11 Neoplasm Metastasis 9 Colonic Neoplasms 9 Lung Neoplasms 8 Uterine Cervical Neoplasms 7 Liver Neoplasms 7 Rectal Neoplasms 6 Glioma 6 Biliary Tract Neoplasms 6 Stomach Neoplasms 5 Triple Negative Breast Neoplasms 4 Squamous Cell Carcinoma of Head and Neck 4 Gastrointestinal Neoplasms 4 Digestive System Neoplasms 4 Carcinoma, Ovarian Epithelial 4 Small Cell Lung Carcinoma 3 Sarcoma 3 Recurrence 3 Peritoneal Neoplasms 3 Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Pancreatic Neoplasms 3

Interventions

pembrolizumab 2 durvalumab 2 Paclitaxel 2 Nivolumab 2 Ipilimumab 2 Doxorubicin 2 zanidatamab 1 veliparib 1 tucatinib 1 trilaciclib 1 trebananib 1 trastuzumab duocarmazine 1 talazoparib 1 spartalizumab 1 selinexor 1 sarilumab 1 pexidartinib 1 pertuzumab 1 pazopanib 1 patritumab 1 olaparib 1 niraparib 1 neratinib 1 ganitumab 1 dostarlimab 1 cemiplimab 1 balstilimab 1 abemaciclib 1 Trastuzumab 1 Standard of Care 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Hemangiosarcoma × Bevacizumab × 90 days × Clear all

NCT01303497 2026-03-13

ANGIO-TAX+

Centre Oscar Lambret

Phase 2 Completed

Hemangiosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡